ITM-41

ITM-41 is a targeted radiopharmaceutical therapeutic candidate consisting of no-carrier-added lutetium-177 chelated to the bisphosphonate zoledronic acid, designed to deliver beta-emitting radionuclide therapy selectively to bone lesions. By exploiting the high affinity of zoledronic acid for hydroxyapatite in actively remodeling bone, ITM-41 aims to concentrate Lu-177 radiation within osteoblastic tumor sites, such as osteosarcoma and bone metastases, while limiting off-target exposure. The agent is being developed by ITM Isotope Technologies Munich and its strategic partner Grand Pharma, and is currently in preclinical development for malignant bone disease including osteosarcoma and bone metastases.[2][7][9][14][15]

Other names

n.c.a. 177Lu-zoledronateno-carrier-added 177Lu-zoledronateno-carrier-added177Lu-zoledronateno-carrier-added-177Lu-zoledronate177Lu-zoledronate